Exhibit 99.1 DURHAM, NC – May 7, 2024 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 30, 2024. First Quarter 2024 Financial Results: *See below under "Use of Non-GAAP Financial Measures" for more details. The following table represents net sales by geographic region, and by business, for the three months ended March 30, 2024 and April 1, 2023: (a) Sales from the SonicOne produ ...

DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2024 before the market opens on Tuesday, May 7, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 a ...

Innovations For Active Healing Agenda and Speakers Mark Singleton Senior Vice-President and Chief Financial Officer Forward Looking Statements and Use of Estimates Use of Estimates Unless otherwise indicated, information contained in this presentation concerning our industry, competitive position and the markets in which Bioventus operates is based on information from independent industry and research organizations, other third-party sources and management estimates. Management estimates are derived from pu ...

Bioventus Inc. (NASDAQ:BVS) Q4 2023 Earnings Conference Call March 12, 2024 8:30 AM ET Company Participants Dave Crawford - Vice President, Investor Relations Rob Claypoole - President and Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group Caitlin Cronin d - Canaccord Genuity Operator Good day, and welcome to the Bioventus Inc. Fourth Quarter 2023 Earnings Conference Call. [Operator Instruct ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------------------------------|-------|--------------------------|-------|--------------------------------------|-------|-------|----------------|-------|------------------------------|-------|-----------------------------------|-------|------------------------------------| | Year Ended December 31, 2022 \nReported GAAP measure | $ | Gross Profit \n331,080 | $ | Operating Expenses (a) ...

SECURITIES AND EXCHANGE COMMISSION ________________ ________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-37844 (Exact Name of Registrant as Specified in Its Charter) | --- | |-----------------------------| | | | | | Accelera ...

gilaxia Bioventus Inc. (NASDAQ:BVS) has emerged as an impressive turnaround story moving forward from its troubled post-IPO period where the company faced a major setback from its failed acquisition of "CartiHeal". The stock has more than doubled over the past year with the leader in therapeutic injections for osteoarthritis capturing a new round of operating momentum in recent quarters. Indeed, we last covered BVS back in October highlighting the improving outlook which was ultimately confirmed by a strong ...

DURHAM, N.C., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it has entered into an Amendment No. 5 (the "Amendment") to the Credit and Guaranty Agreement, between the Company, Wells Fargo Bank, National Association as Administrative Agent and Collateral Agent, and the Lenders from time to time party thereto, dated as of December 6, 2019 and as amended on August 29, 2021, October 29, 2021, ...

Bioventus Inc. (NASDAQ:BVS) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Dave Crawford - Vice President, Investor Relations Tony Bihl - Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Lilia-Celine Lozada - JPMorgan Bill Plovanic - Canaccord Operator Thank you for standing by. My name is Dustin, and I will be your conference operator today. This time, I would like to ...

Financial Performance - Third quarter revenue decreased by 6% to $121 million compared to the prior year quarter[28] - Adjusted EBITDA was $22 million, even compared to the prior year quarter[28] - Year-to-date adjusted EBITDA increased more than $15 million, representing a 30% increase[22] - Adjusted operating expenses decreased almost $9 million due to restructuring benefits, spending discipline, and the Wound Business divestiture[46] - The company now expects 2023 net sales to be in the range of $498 million to $505 million[69] - The company now expects 2023 adjusted diluted loss per share to be a loss of $0.12 to a loss of $0.09[69] Segment Performance - International net sales grew 18%, and constant currency growth was 16%[40] - Surgical Solutions revenue decreased, with Restorative Therapies falling 28%[32] - Pain Treatments increased 3% compared to prior year, with double-digit volume growth driven by Durolane[60,45] Non-GAAP Measures - Non-GAAP Gross Margin was 74.8%[75] - Non-GAAP Operating Income was $20.396 million[75] - Non-GAAP Earnings per share was $0.05[75]